ATE310531T1 - Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung - Google Patents

Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung

Info

Publication number
ATE310531T1
ATE310531T1 AT99115245T AT99115245T ATE310531T1 AT E310531 T1 ATE310531 T1 AT E310531T1 AT 99115245 T AT99115245 T AT 99115245T AT 99115245 T AT99115245 T AT 99115245T AT E310531 T1 ATE310531 T1 AT E310531T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
hedgehog proteins
stabilized pharmaceutical
ions
hedgehog
Prior art date
Application number
AT99115245T
Other languages
English (en)
Inventor
Apollon Papadimitriou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/de
Application filed filed Critical
Application granted granted Critical
Publication of ATE310531T1 publication Critical patent/ATE310531T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99115245T 1998-08-07 1999-08-02 Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung ATE310531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (de) 1998-08-07 1998-08-07 Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung
EP98116734 1998-09-03

Publications (1)

Publication Number Publication Date
ATE310531T1 true ATE310531T1 (de) 2005-12-15

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99115245T ATE310531T1 (de) 1998-08-07 1999-08-02 Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung

Country Status (15)

Country Link
US (1) US6207718B1 (de)
EP (1) EP0978285B1 (de)
JP (1) JP3567103B2 (de)
CN (1) CN1244429A (de)
AT (1) ATE310531T1 (de)
AU (1) AU761341B2 (de)
CA (1) CA2279743C (de)
DE (1) DE69928472T2 (de)
DK (1) DK0978285T3 (de)
ES (1) ES2253851T3 (de)
HK (1) HK1025740A1 (de)
HU (1) HUP9902655A3 (de)
IL (1) IL131238A (de)
MA (1) MA26667A1 (de)
NO (1) NO993804L (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312009A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
EP1557427A3 (de) * 1998-04-30 2005-10-19 Curis, Inc. Hedgehog-Protein-Konjugat
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (en) * 1999-07-29 2001-01-29 Bernard Charles Sherman Stabilized cefuroxime axetil
WO2001082994A1 (en) * 2000-04-28 2001-11-08 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (de) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP2125024B1 (de) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Gezielte intrazelluläre abgabe von antiviralen mitteln
WO2009006097A1 (en) * 2007-06-29 2009-01-08 Johnson & Johnson Regenerative Therapeutics, Llc Liquid protein formulations comprising gdf-5 for use at elevated temperatures
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) * 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
US7947649B2 (en) * 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
EP2478101A1 (de) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1-zielgene als wirkstofftargets zur behandlung von krebs
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
US11633458B2 (en) 2013-11-08 2023-04-25 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CN110248648B (zh) * 2016-11-16 2023-02-24 艾维塔生物医学公司 细胞膜结合信号因子的应用
CN111356447B (zh) * 2017-11-16 2023-03-24 艾维塔生物医学公司 细胞膜结合信号传导因子的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
JPH09509574A (ja) 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (de) 1998-02-04 2006-06-28 Curis, Inc. Pharmazeutische Zusammensetzungen von Hedgehog-Proteinen und deren Verwendung
EP0953575A1 (de) 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung
EP1557427A3 (de) 1998-04-30 2005-10-19 Curis, Inc. Hedgehog-Protein-Konjugat

Also Published As

Publication number Publication date
DE69928472T2 (de) 2006-08-10
HK1025740A1 (en) 2000-11-24
EP0978285A1 (de) 2000-02-09
NO993804L (no) 2000-02-08
JP3567103B2 (ja) 2004-09-22
IL131238A (en) 2005-07-25
AU4344899A (en) 2000-03-02
MA26667A1 (fr) 2004-12-20
DE69928472D1 (de) 2005-12-29
HUP9902655A3 (en) 2000-12-28
CN1244429A (zh) 2000-02-16
AU761341B2 (en) 2003-06-05
US6207718B1 (en) 2001-03-27
CA2279743A1 (en) 2000-02-07
ES2253851T3 (es) 2006-06-01
HU9902655D0 (en) 1999-10-28
NO993804D0 (no) 1999-08-06
IL131238A0 (en) 2001-01-28
DK0978285T3 (da) 2006-03-27
HUP9902655A2 (hu) 2000-08-28
JP2000063283A (ja) 2000-02-29
CA2279743C (en) 2005-05-10
EP0978285B1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE310531T1 (de) Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung
DE69924232D1 (de) Stabilisierte insulin-zubereitungen
ATE409496T1 (de) Hautdesodorierende und desinfizierende zubereitung
BR9900685B1 (pt) composição sólida desodorante e utilização cosmética de uma composição sólida.
DE60103351D1 (de) Zusammensetzung zur Bekämpfung von Ektoparasiten
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
DE60107445D1 (de) Zusammensetzung und methode zur geruchsverringerung
DE69625926T2 (de) Absorbierende zusammensetzung und saugfähiges wegwerfkleidungsstück, welches dasselbe enthält
BR9913912A (pt) Métodos e composições para tratamento de doenças mediadas por receptor
DE60133802D1 (de) Verwendung von säurestabilen proteasen in tierfutter
PE14199A1 (es) Agonistas de 5-ht1f
BR0007035A (pt) Métodos de controle de pragas de agrótis
DE69130880D1 (de) Enzym-stabilisierende Zusammensetzung und deren Verwendung in stabilisierten Enzym enthaltenden verstärkten Waschmittelzusammensetzungen
BR0009502A (pt) Componente de amaciamento de tecido
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
DE69717101T2 (de) VERWENDUNG VON alpha-ALKYLGLUCOSIDEN UND DEREN ESTERN ALS ANTIMIKROBIELLE EMULGATOREN
ID25478A (id) Agonis 5-ht1f
DE59806013D1 (de) Aktivchlorabspaltender Toilettenreinigungsblock
BR0009469A (pt) Tablete perfumado de detergente
BRPI0410150A (pt) método de neutralizar ou reduzir odores associados com fluidos ou sólidos corporais, uso de uma composição de materiais de fragráncia, e, artigo
BR9903555A (pt) Composição farmacêutica de proteìnas de ouriço e seu uso
BRPI0411435A (pt) método para controlar mau cheiro, e, composição desodorizante
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ATE352327T1 (de) Beseitigung von körpergerüchen des weiblichen körpers
DE60217720D1 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0978285

Country of ref document: EP

REN Ceased due to non-payment of the annual fee